The 30 most obese countries in the world in 2018 represent a huge (pun intended) market opportunity for weight loss drugmakers.
Keep Reading →
March 22 - News - Comments
Before we get to the list of 7 over-the-counter diet pills that work without exercise, we should ask ourselves if there exists such a thing. The short answer is no.
Keep Reading →
April 12 - Lists, News - Comments
Are you interested in knowing the 7 Most Popular Diet Pills That Work Fast Without Exercise? I mean what better way to lose weight than to simply pop some pills and let the fat...
Keep Reading →
March 15 - Lists, News - Comments
The 10 best performing weight loss companies have found success in an increasingly competitive environment, one which is pitting supplement providers, medical device makers, weight...
Keep Reading →
March 9 - Lists, News - Comments
The worries about the election and the ongoing uncertainty about the path of interest-rate increases have been keeping investors on the sidelines.
Keep Reading →
December 12 - Hedge Funds, News - Comments
Although a great movie, The Wolf of Wall Street left many people thinking penny stocks are somewhat 'untouchable'.
Keep Reading →
June 9 - Hedge Funds, News - Comments
No doubt, penny stocks are for investors with a greater than average risk appetite, but considering their inexpensiveness and the possibility of towering returns, if any of these...
Keep Reading →
March 26 - Hedge Funds, News - Comments
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the government.
Keep Reading →
December 2 - Hedge Funds, News - Comments
Cheyne Capital is one of the few non-U.S firms that we track in our database.
Keep Reading →
October 21 - Hedge Fund Analysis, Hedge Funds, News - Comments
Seth Klarman’s Baupost Group has initiated a new passive stake in Orexigen Therapeutics Inc. (NASDAQ:OREX), a new filing the U.S. Securities and Exchange Commission showed.
Keep Reading →
October 13 - Hedge Funds, News - Comments
Investing in the healthcare sector can be tricky, especially if you're looking for high returns and want to invest in clinical-stage companies, which represent an above-average...
Keep Reading →
September 16 - Hedge Funds, News - Comments
In the first hours of trading, the markets showed slight signs of improvement, impacted by positive jobless claims data.
Keep Reading →
September 10 - Hedge Funds, News - Comments
Jim Tananbaum’s Foresite Capital has filed its latest 13F with the Securities and Exchange Commission for the reporting period of March 31, disclosing the long positions held...
Keep Reading →
May 7 - Hedge Funds, News - Comments
The healthcare sector is usually very attractive to investors, since the companies involved in it have a great potential to grow.
Keep Reading →
December 19 - Hedge Funds, News - Comments
Christopher Medlock James', San Francisco-based, hedge fund Partner Fund Management has raised its position in Orexigen Therapeutics, Inc.
Keep Reading →
December 17 - Hedge Funds, News - Comments
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued a press release pointing out that its marketing partner Eisai had started direct-to-consumer advertising for their obesity drug...
Keep Reading →
September 17 - News - Comments
If you were to ask many market players, hedge funds are seen as useless, outdated financial vehicles of a forgotten age.
Keep Reading →
September 6 - News - Comments
The first guy, Leland Wilson, got kicked out. Never mind that he founded the company, Samuel Colin, senior managing partner at First Manhattan, VIVUS, Inc.
Keep Reading →
September 5 - News - Comments
In the financial world, there are a multitude of metrics shareholders can use to watch their holdings.
Keep Reading →
August 30 - News - Comments
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)'s Belviq, VIVUS, Inc. (NASDAQ:VVUS)'s Qsymia, and Orexigen Therapeutics, Inc. (NASDAQ:OREX)'s Contrave were rejected by the Food and...
Keep Reading →
August 29 - News - Comments
In the financial world, there are many metrics shareholders can use to track their holdings. A duo of the most innovative are hedge fund and insider trading movement.
Keep Reading →
August 23 - News - Comments
The obesity segment of the health care industry is turning into a battleground. VIVUS, Inc.
Keep Reading →
August 23 - News - Comments
After my article on MannKind Corporation (NASDAQ:MNKD) earlier this week, a reader wasn't too happy about my view that the company was overvalued given the most recent phase ...
Keep Reading →
August 19 - News - Comments
Quite a few research papers published recently have shown that mutations in genes can control your appetite and your ability to burn calories.
Keep Reading →
August 11 - News - Comments
The sales come from less than a month on the market -- the drug launched on June 11 and the quarter closed on June 30 -- and can't tell you anything about the long-term potential...
Keep Reading →
August 2 - News - Comments
Arena Pharmaceuticals, Inc.
Keep Reading →
July 31 - News - Comments
The two weight-loss drug approvals in 2012 were the first in more than a decade. The excitement surrounding Arena Pharmaceuticals, Inc.
Keep Reading →
July 28 - News - Comments
"As a founding CEO, over the past 22 years, Leland has secured four drug approvals, an unheard-of achievement for a small pharmaceutical company. He has taken VIVUS, Inc.
Keep Reading →
July 19 - News - Comments
On Saturday, VIVUS, Inc.
Keep Reading →
July 17 - News - Comments
You know Belviq and Qsymia and Contrave and Empatic, but do you recall the still most widely used weight-loss drug of all? It seems almost like ancient history now, but back in...
Keep Reading →
July 3 - News - Comments
After gaining Food and Drug Administration approval nearly a year ago, patients can finally walk into a pharmacy and get their prescription for VIVUS, Inc.
Keep Reading →
July 3 - News - Comments
After almost a decade, the FDA has once again started approving obesity drugs. VIVUS, Inc. (NASDAQ:VVUS)’s Qysmia and Arena Pharmaceuticals, Inc.
Keep Reading →
June 27 - News - Comments
First investors were reminded of the struggle between VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Orexigen Therapeutics, Inc.
Keep Reading →
June 27 - News - Comments
Editor's Note: Related tickers: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS, Inc. (NASDAQ:VVUS), Orexigen Therapeutics, Inc.
Keep Reading →
June 20 - News - Comments
The decision wasn't without debate, though. In fact, the AMA's Council on Science and Public Health actually recommended against calling obesity a disease.
Keep Reading →
June 19 - News - Comments
An FDA approval is the Holy Grail for biotechnology companies and their investors – but a successful launch is the most momentous in producing long-term gains.
Keep Reading →
June 19 - News - Comments
To the average investor, there are dozens of gauges shareholders can use to track publicly traded companies.
Keep Reading →
June 10 - News - Comments
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)' Belviq, the newest offering, looks relatively safe.
Keep Reading →
June 10 - News - Comments
To the average investor, there are plenty of methods shareholders can use to monitor their holdings. A pair of the most useful are hedge fund and insider trading interest.
Keep Reading →
June 3 - News - Comments
As recently as a decade ago, the biggest hurdle for biotech companies wasn't competition from their peers or even the sale price of their drugs.
Keep Reading →
May 29 - News - Comments
VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc.
Keep Reading →
May 28 - News - Comments
Amarin Corporation plc (ADR) (NASDAQ:AMRN) was in 19 hedge funds' portfolio at the end of March.
Keep Reading →
May 28 - News - Comments
Editor's Note: The original article incorrectly stated Schedule IV drugs are the second-most-restrictive.
Keep Reading →
May 24 - News - Comments
The obesity drug space is becoming increasingly complex and hard to predict. After months of waiting patiently, Arena Pharmaceuticals, Inc.
Keep Reading →
May 23 - News - Comments
Obesity is a growing pandemic for many industrialized nations, especially in the U.S., where it now affects almost 36% of adults and 17% of adolescents.
Keep Reading →
May 23 - News - Comments
The rate of worldwide obesity has been marching higher at an extraordinary rate for more than three decades now.
Keep Reading →
May 20 - News - Comments
It wasn't that long ago that obesity drugs were considered a lifestyle drug. Doctors, the Food and Drug Administration, and insurers believed losing weight was a vanity issue.
Keep Reading →
May 16 - News - Comments
Things are beginning to look slightly up for obesity drugmaker VIVUS, Inc. (NASDAQ:VVUS) -- mere weeks before a competing drug from Arena Pharmaceuticals, Inc.
Keep Reading →
May 14 - News - Comments
A sharp drop in Arena Pharmaceuticals (NASDAQ:ARNA) followed after the company reported quarterly earnings and a withdrawal of its Marketing Authorization Application (“MAA”) ...
Keep Reading →
May 13 - News - Comments
VIVUS, Inc. (NASDAQ:VVUS)' Qsymia has not received the unconditional consumer love that investors were hoping.
Keep Reading →
May 6 - News - Comments